TY - JOUR
T1 - Solid dispersions of atorvastatin with Kolliphor RH40
T2 - Enhanced supersaturation and improvement in a hyperlipidemic rat model
AU - Torrado-Salmerón, Carlos
AU - Guarnizo-Herrero, Víctor
AU - Torrado, Guillermo
AU - Peña, M. Ángeles
AU - Torrado-Santiago, Santiago
AU - de la Torre-Iglesias, Paloma Marina
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2023/1/25
Y1 - 2023/1/25
N2 - Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fast-dissolving atorvastatin systems that enhances their anti-hyperlipidemic effect. Solubility and wettability studies allow the development of solid dispersions with low proportions of croscarmellose sodium as hydrophilic carrier. Solid state characterization studies indicated that the addition of Kolliphor® RH40 surfactant to solid dispersions increases intermolecular hydrogen bonding between drug and polymer chains. Dissolution studies in biorelevant Fasted State Simulate Intestinal Fluid (FaSSIF pH 6.5) medium showed for atorvastatin solid dispersion a supersaturation peak of atorvastatin followed by an aggregation/precipitation process. Only the presence of a surfactant such as Kolliphor® RH40 in atorvastatin micellar system, promotes the presence of micelles that achieve delayed recrystallization. Efficacy studies were carried out using a hyperlipidemic model of rats fed with a high- fat diet. The atorvastatin micellar system at doses of 10 mg/kg, revealed a significant improvement in serum levels of total cholesterol, low-density lipoproteins, and triglycerides compared to atorvastatin raw material. This micellar system also exhibited more beneficial effects on liver steatosis, inflammation and ballooning injury.
AB - Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fast-dissolving atorvastatin systems that enhances their anti-hyperlipidemic effect. Solubility and wettability studies allow the development of solid dispersions with low proportions of croscarmellose sodium as hydrophilic carrier. Solid state characterization studies indicated that the addition of Kolliphor® RH40 surfactant to solid dispersions increases intermolecular hydrogen bonding between drug and polymer chains. Dissolution studies in biorelevant Fasted State Simulate Intestinal Fluid (FaSSIF pH 6.5) medium showed for atorvastatin solid dispersion a supersaturation peak of atorvastatin followed by an aggregation/precipitation process. Only the presence of a surfactant such as Kolliphor® RH40 in atorvastatin micellar system, promotes the presence of micelles that achieve delayed recrystallization. Efficacy studies were carried out using a hyperlipidemic model of rats fed with a high- fat diet. The atorvastatin micellar system at doses of 10 mg/kg, revealed a significant improvement in serum levels of total cholesterol, low-density lipoproteins, and triglycerides compared to atorvastatin raw material. This micellar system also exhibited more beneficial effects on liver steatosis, inflammation and ballooning injury.
KW - Atorvastatin
KW - Hyperlipidemia
KW - Liver steatosis
KW - Micellar system
KW - Solid dispersion
KW - Supersaturation
UR - https://www.scopus.com/pages/publications/85145309120
U2 - 10.1016/j.ijpharm.2022.122520
DO - 10.1016/j.ijpharm.2022.122520
M3 - Article
C2 - 36581105
AN - SCOPUS:85145309120
SN - 0378-5173
VL - 631
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 122520
ER -